chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Surgical Intervention

Hematopoietic Stem Cell Transplantation (HSCT)
  • Should be considered in fit patients with high risk chronic lymphocytic leukemia (CLL) who experience disease relapse 24-36 months after first-line therapy, or patients with refractory CLL
  • May be considered as part of a clinical trial for young patients with del(17p)/TP53 mutation with good performancestatus & minimal comorbidities
  • Reports showed an increase in the progression-free survival rate compared to those given chemotherapy alone
  • Allogeneic HSCT is the preferred type of transplantation for CLL patients
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Stephen Padilla, 24 Oct 2017
Cancer drugs approved by the European Medicines Agency (EMA) from 2009 to 2013 have been sold in the market even without evidence of benefit on survival or quality of life (QoL), according to a study. Survival gains over existing treatment options or placebo, if any, are usually marginal.
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017